APX-3330 is under clinical development by Apexian Pharmaceuticals and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect APX-3330’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their APX-3330 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

APX-3330 overview

APX-3330 is under development for the treatment of solid tumors including pancreatic ductal adenocarcinoma, pancreatic ductal adenocarcinoma, endometrial cancer, melanoma, chronic hepatitis C, prostate cancer and colorectal cancer, diabetic macular edema, non proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), hematological cancers including acute lymphoblastic leukemia, malignant peripheral nerve sheath tumor (MPNST), laser-induced choroidal neovascularization, tuberous sclerosis complex (TSC), inflammation, inflammatory bowel disease, wet age-related macular degeneration, gall bladder cancer, hepatocellular cancer, bladder cancer and ovarian cancer. It is a new chemical entity and is administered orally as a tablet. The drug candidate acts by targeting Ref-1 and TNF synthesis.

It was also under development for the treatment of hepatic failure and chemotherapy-induced peripheral neuropathy.

Apexian Pharmaceuticals overview

Apexian Pharmaceuticals is a clinical-stage biotechnology company.It develops and commercializes pharmaceuticals for the treatment of cancer and ocular diseases. The company is headquartered in Indianapolis, Indiana, United States.

Quick View APX-3330 LOA Data

Report Segments
  • Innovator
Drug Name
  • APX-3330
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Genetic Disorders
  • Immunology
  • Infectious Disease
  • Metabolic Disorders
  • Oncology
  • Ophthalmology
  • Toxicology
Key Developers
  • Sponsor Company: Apexian Pharmaceuticals
  • Originator: Eisai
Highest Development Stage
  • Phase II

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.